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Abstract
High-throughput fluorescent intercalator displacement (HT-FID) was adapted to the semi-automated
screening of a commercial compound library containing 60,000 molecules resulting in the discovery
of cytotoxic DNA-targeted agents. Although commercial libraries are routinely screened in drug
discovery efforts, the DNA binding potential of the compounds they contain has largely been
overlooked. HT-FID led to the rapid identification of a number of compounds for which DNA binding
properties were validated through demonstration of concentration-dependent DNA binding and
increased thermal melting of A/T- or G/C-rich DNA sequences. Selected compounds were assayed
further for cell proliferation inhibition in glioblastoma cells. Seven distinct compounds emerged from
this screening procedure that represent structures unknown previously to be capable of targeting
DNA leading to cell death. These agents may represent structures worthy of further modification to
optimally explore their potential as cytotoxic anti-cancer agents. In addition, the general screening
strategy described may find broader impact toward the rapid discovery of DNA targeted agents with
biological activity.
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B-form DNA continues to be an important and viable target in the discovery and development
of novel anti-cancer1-6 and anti-microbial/anti-parasitic7-9 agents. Indeed, it has been noted2
that among new agents in clinical use against cancer (as of 2002), many continue to target DNA
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as a locus for their activities.10 In general, biologically active DNA-targeted compounds, either
wholly synthetic or derived from natural product sources, bind DNA reversibly or modify this
biopolymer covalently leading to the inhibition of transcription and/or DNA replication; while
reversible DNA binding agents can interfere competitively with the proteins necessary for
transcriptional control or processing, covalent lesions can lead to intra- or inter-strand cross
links within genomic DNA, often halting the progression of replication forks. Additionally, in
the case of DNA-targeted anti-parasitic compounds, e.g., anti-trypanosomals, active agents
often target A/T-rich regions of DNA including intrinsically bent kinetoplast minicircles.4,8
Thus, given the clinical potential of DNA targeted agents–from the generation of novel anti-
cancer treatments to unique strategies in the fight against microbial infections and neglected
tropical diseases–the search for new DNA binding agents continues unabated.
Expediting the above search, high-throughput screening (HTS) strategies coupled to focused
compound library approaches are being employed with increasing frequency.3,5,11,12 To date,
most efforts in this area have aimed for the discovery of increasingly selective compounds
targeted to key DNA sequences within genes, usually the binding sites of critical regulatory
proteins.3,5 These efforts have been facilitated by the development of strategies to rapidly
identify site-selective DNA binding agents and to assess their DNA binding properties. Among
the methods employed, fluorescence intercalator displacement (FID)13-15 and cognate site
identifier (CSI) arrays16 have been used successfully. Noteworthy, the FID and CSI strategies
have been combined recently into a single platform for discovery.17
While highly selective DNA binding agents discovered through the above efforts generally are
pursued to enable the “knock out” of key DNA-protein interactions to ultimately alter some
well-defined biological response, it is worth underscoring that virtually all DNA-targeted
agents in active clinical use exhibit very limited site-selectivities, usually 2-4 base pairs only.
18,19 Thus, while efforts aimed at developing agents with increasing DNA specificity are of
keen interest, the continued quest for unique biologically active agents with limited DNA site-
selectivities may similarly lead to interesting and useful compounds.
With the above in mind, we have developed a strategy for the rapid discovery of DNA targeted
compounds that couples fluorescent intercalator displacement (FID) to semi-automated high-
throughput screening technologies (Scheme 1). We demonstrate that a robust HT screen can
be developed to analyze large compound libraries, as demonstrated through our analysis of a
60,000 member commercially-available library, and that validated DNA-targeted hits
discovered in this fashion can lead to agents that are cytotoxic to glioblastoma cancer cells.
While the primary goal of the work described herein was to develop a strategy to expedite the
identification of DNA targeted agents from large libraries, as a side benefit our assay also
provides a rapid means to pre-screen for DNA binding library members that may lead to false-
positive results in assays devoted to the discovery of agents targeted to proteins in the presence
of a DNA substrate, e.g. enzymes involved in repair processes.
HTS assay development and validation
Our HTS strategy was developed from a standard FID approach using calf thymus DNA as a
binding substrate and ethidium bromide as a reporting fluorophore.20 Calf thymus DNA has
the advantage of being a cost-effective HTS substrate approximating all possible combinations
of base pairs. Briefly, in an FID assay, DNA-bound ethidium bromide fluoresces brightly and
when challenged with a competing DNA binding agent, the original level of ethidium bromide
fluorescence is decreased due to its displacement from binding sites.
Initially, we sought to assess the validity of our proposed assay. Using ethidium-bound calf
thymus DNA in conjunction with two well-characterized DNA binding agents, actinomycin
D and netropsin (as G/C-selective intercalating and A/T-selective groove-binding positive
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controls, respectively), or a buffer blank (as a negative control), Z′ score21 analyses were
conducted. Z′ analyses provide a statistical assessment of the reproducibility achievable in an
HT assay: the negative control provides a maximum percent F to be expected in the assay while
positive controls provide a maximum decrease in F to be expected from strong DNA binding
agents–these aspects determine the dynamic range of the assay.
Using the above controls, 20 μL aliquots containing 25 μM compound (or water blanks) were
dispensed into 384 well plates (black Nunc) using a robotic liquid handler (Tecan Freedom
EVO 150). Subsequently, 30 μL aliquots of a solution containing calf thymus DNA, ethidium
bromide, and Tris buffer (pH 7.4) were dispensed into these same plate wells to provide final
concentrations of each well component (21 μM DNA base pair, 6.5 μM ethidium bromide, 100
mM NaCl, 10 mM Tris (pH 7.4), 0.8% DMSO and 10 μM binding agent. The fluorescence
output of each sample well was measured via a Perkin-Elmer Envision 2102 multilabel plate
reader (λex 530 nm, λem 615 nm) and compared to negative controls (no added compound) to
determine percent F decreases. These data (~384 wells, one plate, per positive or negative
agent) revealed that the average percent decrease in F observed for actinomycin D was 63%
while that observed for netropsin was 32%. Using these data a Z′ score of 0.74 was determined
for actinomycin D, well within the acceptable range for Z′ scores (>0.5 to be deemed a viable
assay21) and indicating the viability of our screen. In comparison, a Z′ score of 0.41 was
determined for netropsin; actinomycin D thus was chosen as the exclusive positive parallel
control for all subsequent FID screening.
Application to a compound library
The assay was applied to a commercially available ChemDiv library containing 60,000
compounds with an overall average MW of 300. ChemDiv libraries are widely used in HTS
and contain a cross-section of pharmacophore-rich, drug-like compounds that possess good
ADME profiles. Noteworthy, the DNA binding potential of this library has not been assessed.
Thus, identifying the DNA binding components contained therein may be of broader interest.
Applying our screen to the above library (~10 μM compound/well22) in the presence of both
positive (actinomycin D) and negative (buffer blank) controls revealed that from among the
60,000 compounds examined, 165 produced an F decrease of 25% or greater (Scheme 1) with
the best agents decreasing F between 46% and 30%. Next, from among the 165 compounds
initially identified, 143 available compounds were rescreened twice in independent
experiments using the same FID assay. The re-screens led to the identification of 57 compounds
for which consistent results were obtained and from which 30 compounds were selected for
validation using a non-fluorescence based method.
Validation of hits: non-fluorescent based secondary screening via thermal
melting
The DNA binding activities of the 30 hits identified above were verified using a standard, non-
fluorescence based method: DNA thermal melting.20 ΔTm values were determined through an
examination of DNA hyperchromicity at 260 nm as a function of increased temperature in the
presence of each compound. Upon examination of the 30 hits (in parallel with actinomycin
and netropsin controls) using poly(dA-dT) and a G/C-rich oligonucleotide (to evaluate A/T-
vs. G/C-selectivity, respectively), we confirmed the DNA binding activity of 17 of the original
30 compounds. From these 17 verified DNA binding agents, seven compounds where selected
(1-7, see Fig 1 and Table 1) based on their consistent, strong FID assay responses and high
Tm values, quite similar to actinomycin and netropsin, and similar in Tm behavior to some
synthetic groove binding ligands reported previously by others using this DNA.23
Glass et al. Page 3
Bioorg Med Chem Lett. Author manuscript; available in PMC 2011 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
As shown in Table 1, 1-7 all displayed appreciable %F changes in the HT-FID screen relative
to actinomycin and netropsin. The top compounds selected also exhibited high ΔTm values
quite similar to the values observed for the control DNA binding agents. While not definitive,
the differential responses of these agents towards the thermal melting substrates suggested that
1-6 may be A/T-selective while 7 may be relatively more selective for G/C sites: like the A/
T-selective agent netropsin, 1-6 exhibited no impact on the thermal melting of the G/C
oligonucleotide while increasing the Tm of the A/T substrate; whereas, 7 behaved in a fashion
similar to actinomycin with the G/C oligonucleotide but did not impact the melting of the A/
T substrate. A precise determination of the DNA binding site-selectivities of these agents will
require more rigorous testing.
Determination of relative DNA binding affinities
The relative DNA binding affinities of 1-7 were determined using plate conditions (DNA,
buffer, etc.) similar to those used in the FID screening.24 Thus, the concentrations of each
compound 1-7 required to decrease sample fluorescence to half its original value (FD50) within
the range achievable by each compound were determined (Table 1). Realizing that at this point
in our characterization we do not know: (1) the DNA-binding site sizes associated with these
compounds nor (2) their selectivities beyond tentatively establishing A/T vs. G/C preferences,
two factors that influence the extent of ethidium bromide displacement, it appears that
compounds 1-7 as a group are reasonably strong DNA-binding agents relative to the control
agents studied in parallel. Obviously, a detailed DNA binding characterization through
established techniques is beyond the scope and intention of this report focused on strategies
for rapid discovery.
Assessments of cell growth inhibition and cytotoxicity
Along with their in vitro DNA binding, the relative cell growth inhibition/cytotoxicities of
1-7 against SF767 glioblastoma cells were also evaluated. Cell growth and survival assays
were determined in triplicate using a standard MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium) assay25: cells (2000) grown for 24 h were treated with increasing
concentrations of 1-7; cell survival after 72 h of treatment was determined by addition of the
MTT reagent and standard protocols to assess the remaining number of viable cells. A media-
only blank was included in each treatment group to serve as a background control. Fig 2
illustrates the % surviving cells after 72 h of treatment at a given compound concentration;
plots were used to graphically determine LC50 values (Table 1). Compounds 2-6 inhibited cell
growth while 1 and 7 showed no significant effect at the concentrations tested. Compound 2
produced the lowest LC50 value of 2.6 μM, while 4 and 5, the latter resembling a benzimidazole-
based DNA groove binder, exhibited the next lowest LC50 values. In comparison to the above,
3 and 6 produced intermediate results.
Conclusions
We have described a semi-automated FID-based HT screen for the rapid discovery of DNA
binding components from compound libraries. This screen has the potential to be widely
applicable in the discovery of new DNA binding agents as well as to permit the pre-screening
of libraries when knowledge of the presence of DNA binding components would be useful. It
is evident that this screen can select diverse and unique DNA binding structures, as in our
discovery of 1-7. Indeed, a perusal of the literature indicates that DNA binding properties and
cytotoxicities have not been reported for the compounds selected. Currently, structure-activity
relationships for these compounds are being assessed as well as more detailed analyses of their
DNA binding characteristics.
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Figure 1.
Structures of select validated DNA binding hits 1-7 discovered as described in Scheme 1.
Glass et al. Page 6
Bioorg Med Chem Lett. Author manuscript; available in PMC 2011 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
Results from MTT assays that examined the % survival of SF767 glioblastoma cells treated
for 72 hours with increasing concentrations of 1-7 (1: black squares; 2: black circles; 3: white
diamonds; 4: grey circles; 5: black triangles; 6: white squares; 7: grey triangles). These data
were used to determine LC50 values (Table 1).
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Scheme 1.
Semi-automated high-throughput screening strategy leading to the selection of DNA binding
components from a compound library.
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